Adcirca contraindicated with riociguat
The summary of product characteristics for Adcirca (tadalafil; Eli Lilly) now states that the co-administration of phosphodiesterase 5 (PDE5) inhibitors, including tadalafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it could lead to symptomatic hypotension.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069236
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com